<?xml version='1.0' encoding='utf-8'?>
<document id="30941173"><sentence text="Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4." /><sentence text="Human organic anion transporter 4 (hOAT4) belongs to a family of multispecific organic anion transporters that play critical roles in the disposition of numerous drugs and therefore are the major sites for drug-drug interaction" /><sentence text=" Drug-drug interactions contribute significantly to the individual variation in drug response" /><sentence text=" hOAT4 is expressed in the kidney and placenta" /><sentence text=" In the current study, we examined the interaction of 36 anticancer drugs with hOAT4 in kidney COS-7 cells and placenta BeWo cells" /><sentence text=" Among the drugs tested, only epirubicin hydrochloride and dabrafenib mesylate exhibited &gt; 50% cis-inhibitory effect, in COS-7 cells, on hOAT4-mediated uptake of estrone sulfate, a prototypical substrate for the transporter"><entity charOffset="30-54" id="DDI-PubMed.30941173.s6.e0" text="epirubicin hydrochloride" /><entity charOffset="59-78" id="DDI-PubMed.30941173.s6.e1" text="dabrafenib mesylate" /><entity charOffset="162-177" id="DDI-PubMed.30941173.s6.e2" text="estrone sulfate" /><pair ddi="false" e1="DDI-PubMed.30941173.s6.e0" e2="DDI-PubMed.30941173.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30941173.s6.e0" e2="DDI-PubMed.30941173.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30941173.s6.e0" e2="DDI-PubMed.30941173.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30941173.s6.e1" e2="DDI-PubMed.30941173.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30941173.s6.e1" e2="DDI-PubMed.30941173.s6.e2" /></sentence><sentence text=" The IC50 values for epirubicin hydrochloride and dabrafenib mesylate were 5"><entity charOffset="21-45" id="DDI-PubMed.30941173.s7.e0" text="epirubicin hydrochloride" /><entity charOffset="50-69" id="DDI-PubMed.30941173.s7.e1" text="dabrafenib mesylate" /><pair ddi="false" e1="DDI-PubMed.30941173.s7.e0" e2="DDI-PubMed.30941173.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30941173.s7.e0" e2="DDI-PubMed.30941173.s7.e1" /></sentence><sentence text="24±0" /><sentence text="95 μM and 8" /><sentence text="30±3" /><sentence text="30 μM, respectively" /><sentence text=" Dixon plot analysis revealed that inhibition by epirubicin hydrochloride was noncompetitive with a Ki = 3 μM whereas inhibition by dabrafenib mesylate was competitive with a Ki = 4"><entity charOffset="49-73" id="DDI-PubMed.30941173.s12.e0" text="epirubicin hydrochloride" /><entity charOffset="132-151" id="DDI-PubMed.30941173.s12.e1" text="dabrafenib mesylate" /><pair ddi="false" e1="DDI-PubMed.30941173.s12.e0" e2="DDI-PubMed.30941173.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30941173.s12.e0" e2="DDI-PubMed.30941173.s12.e1" /></sentence><sentence text="26 μM" /><sentence text=" Our results established that epirubicin hydrochloride and dabrafenib mesylate are inhibitors of hOAT4"><entity charOffset="30-54" id="DDI-PubMed.30941173.s14.e0" text="epirubicin hydrochloride" /><entity charOffset="59-78" id="DDI-PubMed.30941173.s14.e1" text="dabrafenib mesylate" /><pair ddi="false" e1="DDI-PubMed.30941173.s14.e0" e2="DDI-PubMed.30941173.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30941173.s14.e0" e2="DDI-PubMed.30941173.s14.e1" /></sentence><sentence text=" Furthermore, by comparing our data with clinically relevant exposures of these drugs, we conclude that although the tendency for dabrafenib mesylate to cause drug-drug interaction through hOAT4 is insignificant in the kidney, the propensity for epirubicin hydrochloride to cause drug-drug interaction is high"><entity charOffset="130-149" id="DDI-PubMed.30941173.s15.e0" text="dabrafenib mesylate" /><entity charOffset="246-270" id="DDI-PubMed.30941173.s15.e1" text="epirubicin hydrochloride" /><pair ddi="false" e1="DDI-PubMed.30941173.s15.e0" e2="DDI-PubMed.30941173.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30941173.s15.e0" e2="DDI-PubMed.30941173.s15.e1" /></sentence><sentence text="" /></document>